Vernalis PLC Notice of Annual Report and AGM (0137V)
02 November 2017 - 6:00PM
UK Regulatory
TIDMVER
RNS Number : 0137V
Vernalis PLC
02 November 2017
2 November 2017
NOTICE OF REPORT AND ACCOUNTS AND ANNUAL GENERAL MEETING
Vernalis plc (LSE: VER) gives notice of the following:
-- that copies of the Group's Report and Accounts for the 12
month period ended 30 June 2017, the Notice of Annual General
Meeting ("AGM") and Form of Proxy have been sent to shareholders.
These documents are also available on the Investor Centre page of
the Company's web site at www.vernalis.com; and
-- that its AGM will be held on Thursday 14 December 2017 at the
offices of Covington & Burling LLP, 265 Strand, London, WC2R
1BH at 10.30 am.
- ends -
Enquiries:
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive
Officer
David Mackney, Chief Financial
Officer
Canaccord Genuity Limited
(Nominated Adviser and Joint
Broker): +44 (0) 20 7523 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
Shore Capital (Joint Broker): +44 (0) 20 7408 4090
Toby Gibbs
Mark Percy
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Stern Investor Relations: +1 212 362 1200
Stephanie Ascher
Jane Urheim
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR,
targeting the US prescription cough-cold market; Moxatag(R) , a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last ten years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris.
For further information about Vernalis, please visit
www.vernalis.com.
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that
reflect the Company's current expectations regarding future events
including the clinical development and regulatory clearance of the
Company's products, the Company's ability to find partners for the
development and commercialisation of its NCE pipeline, the
Company's ability to successfully commercialise its cough-cold
products and Moxatag(R) through its own salesforce, as well as the
Company's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a
number of factors including the success of the Company's research
strategies, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies, the
uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable
partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from
such transactions, the acceptance of Tuzistra(R) XR, Moxatag(R) ,
frovatriptan and other products by consumers and medical
professionals, the successful integration of completed mergers and
acquisitions and achievement of expected synergies from such
transactions, and the ability of the Company to identify and
consummate suitable strategic and business combination
transactions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFDAFMSFWSEES
(END) Dow Jones Newswires
November 02, 2017 03:00 ET (07:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024